Aranscia’s Houda Hachad a Featured Guest in DOTmed

Houda Hachad, PharmD, M.Res, shared her predictions for the state of healthcare in 2025, alongside 6 other healthcare executives.

“We can now confidently transform experimental PGx programs into comprehensive PGx hubs for larger patient communities. We will see amplification in the use of PGx test results by healthcare providers to elevate their therapeutic decisions and select effective interventions sooner.” – Houda Hachad, PharmD, M. Res, Vice President of Clinical Operations at Aranscia

Click here to read more about Houda’s predictions for 2025 in DOTmed’s article, “Seven healthcare execs share their 2025 predictions.”